

人福醫藥 (600079.CH)

製劑出口或支撐業績爆發


中國 | 醫藥 | 公司研報

30 November 2016

前三季業績大增

人福醫藥前三季度實現收入 87.8 億元，同比增 26.6%，歸母淨利潤 6.2 億元，同比增 41.2%，主要得益於 EPIC Pharm 等並表的影響。剔除 EPIC 淨利潤、並購費用以及新增財務費用後，調整後扣非歸母淨利潤為 4.7 億元，按年 13.6%，符合公司內生增速約 15% 的預期。

High performance growth



Source: Company report, Phillip Securities (HK) Research

公司醫藥工業維持穩健增長，預計宜昌人福前三季度同比增長超過 12%。公司已在醫藥產業多個細分市場佔據領先優勢，目前已佈局包括麻醉、生育調節藥物和甬體激素、血製品、維吾爾藥等，醫療服務方面，公司業已收購和建立 12 家醫院，形成產業規模。

製劑出口或支撐業績爆發

繼成功並購 EPIC 製藥公司獲得美國麻醉藥管制牌照及產線後，人福醫藥於海外佈局取得重大突破，同時受益於專利皮膚藥放量及軟膠囊訂單盈利能力的提升，公司國際化前景樂觀。

公司自 2014 年開始大力投入製劑出口業務，目前已在宜昌、武漢和非洲馬里建立符合 cGMP 認證要求的生產車間，其中武漢普克軟膠囊生產線已零缺陷通過美國 FDA 核查。而且，公司在海外儲備了 40 多個 ANDA/NDA 專案品種，結合 Epic 優秀的產品線及海外管道，預計將為公司未來業績爆發提供支撐。

定向增發募資彰顯大股東信心

公司公告擬向大股東當代科技非公開發行股票，發行價格為 17.76 元/股，募集資金不超過 28 億元，鎖定期三年，用於償還銀行貸款和超短期融資券。如果成功發行，大股東持股比例將從 24.49% 提升至 32.74%。

買入 (維持)

現價: CNY 20.19

(現價截至 11 月 28 日)

目標價: CNY 26.95 (+33.5%)

公司資料

普通股股東 (百萬股):	1,286
市值 (人民幣百萬元):	25,965
52 周 最高價/最低價 (人民幣元):	23.28/ 14.60

主要股東, %

武漢當代科技產業集團:	24.49
-------------	-------

股價表現, %

	1 個月	3 個月	1 年
人福醫藥	-4.93	-5.42	1.83
上證指數	-9.08	-11.73	12.41

股價 & 上證指數



Source: Phillip Securities (HK) Research

財務資料

CNY mn	FY14	FY15	FY16E	FY17E
Net Sales	7000	9991	12512	15399
Net Profit	452	654	881	1155
EPS, CNY	0.43	0.52	0.68	0.90
PER, x	47.51	38.83	29.48	22.48
BVPS, CNY	4.47	6.13	7.84	8.60
P/BV, x	4.52	3.29	2.58	2.35
ROE, %	9.97	10.38	9.22	11.08
Debt/Equity (%)	112.42	97.69	122.22	122.22

Source: Company reports, Phillip Securities Est.

研究分析員

范國和


(+ 86 21 51699400-110)

fangguohe@phillip.com.cn

此前，因收購 EPIC 及投資並購醫院等，公司負債增加較多，截止 9 月 30 日負債總額達 138.1 億元，較年初增加 48.4 億元，進而導致前三季度財務費用增加 0.84 億元。屆時，募資將改善公司財務結構，令資產負債率降至約 55%，並緩解財務壓力，財務費用有望減少逾億元。

總體而言，人福醫藥現有醫藥工業業務穩健增長，國際化戰略及醫療服務業務持續推進，產品線儲備豐富，業績有望持續大增。大股東全額參與非公開股票發行亦彰顯信心，我們給予其對應 2017 年每股收益 30 倍估值，目標價為 26.95 元，維持“買入”評級。(現價截至 11 月 28 日)

Historical P/E Valuation



Source: Bloomberg, Phillip Securities (HK) Research

風險

醫療服務拓展低於預期；
醫保控費負面影響超預期。

財務報告

Valuation Ratios					
Price Earnings	48.65	47.51	38.83	29.48	22.48
Price to Book	4.92	4.52	3.29	2.58	2.35
Dividend Yield	0.30%	0.00%	0.50%	0.69%	0.89%
Per share data(CNY)					
EPS Adjusted	0.42	0.43	0.52	0.68	0.90
Book Value Per Share	4.11	4.47	6.13	7.84	8.60
Dividends Per Share	0.06	0.00	0.10	0.14	0.18
Growth & Margin					
Revenue growth	-	17.32%	42.73%	25.23%	23.07%
Gross profit growth	-	16.75%	25.47%	25.07%	23.42%
Net profit growth	-	8.14%	44.72%	34.73%	31.13%
Gross Margin	41.09%	40.89%	35.95%	35.90%	36.00%
Operating Margin	14.96%	13.40%	10.85%	10.80%	11.00%
Net Profit Margin	7.00%	6.45%	6.54%	7.04%	7.50%
Dividend Payout Ratio %	15.19%	0.00%	19.67%	20.44%	20.04%
Key ratios					
Return on Assets	4.76%	4.13%	4.31%	4.38%	4.99%
Return on Equity	11.35%	9.97%	10.38%	9.22%	11.08%
Liability ratio	47.66%	52.92%	49.42%	55.00%	55.00%
Effective Tax Rate	21.91%	22.61%	20.41%	20.41%	20.41%
Income Statement(CNY: mn)					
Revenue	5,967	7,000	9,991	12,512	15,399
- Cost of Goods Sold	3,515	4,138	6,400	8,020	9,855
Gross Income	2,452	2,862	3,591	4,492	5,544
- Selling, General & Admin Expenses	1,559	1,924	2,507	3,140	3,850
Operating Income	893	938	1,084	1,351	1,694
- Interest Expense	168	197	242	342	250
- Net Non-Operating Losses (Gains)	-50	-80	-227	-435	-450
Pretax Income	770	821	1,072	1,444	1,894
- Income Tax Expense	169	186	219	295	386
Income Before XO Items	601	636	853	1,150	1,507
- Minority Interests	183	184	199	269	352
Net Profit	418	452	654	881	1,155

Source: Company, Phillip Securities (HK) Research Estimates

(財務資料截至 11 月 28 日)

PHILLIP RESEARCH STOCK SELECTION SYSTEMS

Total Return	Recommendation	Rating	Remarks
>+20%	Buy	1	>20% upside from the current price
+5% to +20%	Accumulate	2	+5% to +20% upside from the current price
-5% to +5%	Neutral	3	Trade within $\pm 5\%$ from the current price
-5% to -20%	Reduce	4	-5% to -20% downside from the current price
<-20%	Sell	5	>20% downside from the current price

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation

GENERAL DISCLAIMER

This publication is prepared by Phillip Securities (Hong Kong) Ltd ("Phillip Securities"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

Disclosure of Interest

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report.

Firm's Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

Availability

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited ("PSHK") believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product's risks, please visit the Risk Disclosures Statement on <http://www.phillip.com.hk>.

© 2016 Phillip Securities (Hong Kong) Limited

Contact Information (Regional Member Companies)

SINGAPORE**Phillip Securities Pte Ltd**

Raffles City Tower
250, North Bridge Road #06-00
Singapore 179101
Tel : (65) 6533 6001
Fax : (65) 6535 6631
Website: www.poems.com.sg

HONG KONG**Phillip Securities (HK) Ltd**

Exchange Participant of the Stock Exchange of Hong Kong
11/F United Centre 95 Queensway
Hong Kong
Tel (852) 22776600
Fax (852) 28685307
Websites: www.phillip.com.hk

INDONESIA**PT Phillip Securities Indonesia**

ANZ Tower Level 23B,
Jl Jend Sudirman Kav 33A
Jakarta 10220 – Indonesia
Tel (62-21) 57900800
Fax (62-21) 57900809
Website: www.phillip.co.id

THAILAND**Phillip Securities (Thailand) Public Co. Ltd**

15th Floor, Vorawat Building,
849 Silom Road, Silom, Bangrak,
Bangkok 10500 Thailand
Tel (66-2) 6351700 / 22680999
Fax (66-2) 22680921
Website: www.phillip.co.th

UNITED KINGDOM**King & Shaxson Capital Limited**

6th Floor, Candlewick House,
120 Cannon Street,
London, EC4N 6AS
Tel (44-20) 7426 5950
Fax (44-20) 7626 1757
Website: www.kingandshaxson.com

AUSTRALIA**PhillipCapital Australia**

Level 12, 15 William Street,
Melbourne, Victoria 3000, Australia
Tel (613) 96188238
Fax (613) 92002272
Website: www.phillipcapital.com.au

MALAYSIA**Phillip Capital Management Sdn Bhd**

B-3-6 Block B Level 3 Megan Avenue II,
No. 12, Jalan Yap Kwan Seng, 50450
Kuala Lumpur
Tel (603) 21628841
Fax (603) 21665099
Website: www.poems.com.my

JAPAN**PhillipCapital Japan K.K.**

Nagata-cho Bldg.,
8F, 2-4-3 Nagata-cho,
Chiyoda-ku, Tokyo 100-0014
Tel (81-3) 35953631
Fax (81-3) 35953630
Website: www.phillip.co.jp

CHINA**Phillip Financial Advisory (Shanghai) Co. Ltd**

No 436 Hengfeng Road,
Greentech Unit 604,
Postal code 200070
Tel (86-21) 51699400
Fax (86-21) 63532643
Website: www.phillip.com.cn

FRANCE**King & Shaxson Capital Limited**

3rd Floor, 35 Rue de la Bienfaisance 75008
Paris France
Tel (33-1) 45633100
Fax (33-1) 45636017
Website: www.kingandshaxson.com

UNITED STATES**Phillip Futures Inc**

141 W Jackson Blvd Ste 3050
The Chicago Board of Trade Building
Chicago, IL 60604 USA
Tel +1.312.356.9000
Fax +1.312.356.9005